Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by jordon3on Dec 19, 2017 4:43pm
62 Views
Post# 27190681

RE:RE:RE:RE:RE:RE:RE:RE:Outlook 2018---Full NASDAQ listing

RE:RE:RE:RE:RE:RE:RE:RE:Outlook 2018---Full NASDAQ listing

Reverse stock splits

Finally, there's one type of stock split that almost always is bad news for investors. Those are companies that engineer reverse stock splits, by combining existing shares into one new share. For example, a 1-to-10 reverse stock split would trade 40 old shares priced at $2 per share into 4 shares priced at $20.  

Often, the reason companies do this is to meet the listing requirements of major stock exchanges like the New York Stock Exchange and Nasdaq, both of which require stocks listed on their respective exchanges to have a minimum value of $1 per share. Generally, the prognoses of companies that undertake reverse splits are poor. A recent study confirms a suspicion that reverse-split stocks will continue to lose value.

–Chris Horymski

Bullboard Posts